Recently, a related approach has been proposed in which tumors exhibiting the sparingly immunogenic viral latency program, latency I, are driven into more immunogenic latency II or III transcriptional programs, making the tumor cells a target for EBV-specific cytotoxic T lymphocytes (CTLs) that recognize antigens of other latency proteins (e.g., latent membrane protein 1 [LMP1], EBNA3, etc.)(33). This evidence concerns the gene PDLIM7 and neoplasm.